SCHEMBL4701904

SCHEMBL4701904

CC(C)(C(=O)N1CCCCCC1)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 9/20 0.48
CNR1 P21554 2/20 0.48
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
AKR1C3 P42330 1/20 0.47
RORC P51449 1/20 0.47
RAB9A P51151 3/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 2/20 0.45
POLB P06746 1/20 0.45
CNR2 P34972 1/20 0.44
EP300 Q09472 1/20 0.44
CREBBP Q92793 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17055218 0.81 RORC (0.45) HSD11B1CNR1HPGDSMN1; SMN2HTT
SCHEMBL27667271 0.79 PDK2 (0.49) HSD11B1CNR1MAPTEP300CREBBP
SCHEMBL20557109 0.78 CNR1 (0.41) HSD11B1CNR1HPGDSMN1; SMN2HTT
SCHEMBL20557108 0.78 CNR1 (0.41) HSD11B1CNR1HPGDSMN1; SMN2HTT
SCHEMBL4701459 0.78 PDK2 (0.42) HSD11B1CNR1ALDH1A1POLBCNR2
SCHEMBL13106518 0.78 EPHX2 (0.50) HSD11B1SMN1; SMN2LMNARAB9ANPC1
SCHEMBL4705022 0.77 HSD11B1 (0.52) HSD11B1CNR1EP300CREBBPKMT2A
SCHEMBL4704927 0.77 HSD11B1 (0.59) HSD11B1HPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL23903336 0.76 ALDH1A1 (0.69) HPGDSMN1; SMN2HTTALDH1A1LMNA
SCHEMBL11268727 0.76 SMN1; SMN2 (0.44) HSD11B1CNR1HPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758582-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1758582-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP claimed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US claimed
WO-2006002349-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO claimed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009471-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CNR1 516/4885HPGD 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.